Mps-112, Mps-106, Mps-213, Mps-102, Mps-216, Mps-103, Mps-215, Mps-214, D-Ala-Lys-Cha-Val-Ala-Ala-Trp-Thr-Leu-Lys-Ala-Ala-D-Ala, Mps-200

6 trials 4 recruiting

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

4 Recruiting

1 Completed trials

4 Sponsors

11 Countries

Phase III

Phase II

Phase I (FiH)

Phase III: 1 Phase II: 4 Phase I (FiH): 1

Indications tested

Lymphoma 1 Ovarian cancer recurrent 1 Ovarian cancer 1 Non-small cell lung cancer 1

Sponsors using this IMP

Fondazione Ricerca Traslazionale 2 MoonLake Immunotherapeutics AG 2 Asso De Recherche Cancers Gynecologiques 1 Association Gercor 1

All trials

6 total

Maintenance With OSE2101 Plus FOLFIRI, or FOLFIRI After FOLFIRINOX-based Induction Therapy in Locally Advanced or Metastatic Pancreatic Duct… Pending

2024-518139-12-00 Phase II 1 country Association Gercor
A multicenter, Phase II, open label, randomized trial evaluating the efficacy of Tedopi plus docetaxel or Tedopi plus nivolumab as second-li… Recruiting

2024-518224-74-01 Phase II 3 countries Fondazione Ricerca Traslazionale
Randomized phase II trial of Cemiplimab plus OSE2101 (TEDOPI®) as maintenance therapy in ctDNA positive NSCLC. Recruiting

2024-519262-42-00 Phase II 1 country Fondazione Ricerca Traslazionale
A phase 3 trial comparing a therapeutic cancer vaccine OSE2101 to chemotherapy docetaxel in patients with metastatic Non-Small Cell Lung Can… Recruiting

2023-509340-10-00 Phase III 11 countries OSE Immunotherapeutics
A multicenter phase 1/2 study of OSE-279, a PD-1 blocking monoclonal antibody, in subjects with advanced solid tumors or lymphomas Recruiting

2024-514826-22-00 Phase I (FiH) 3 countries OSE Immunotherapeutics
Evaluation of two maintenance therapies (OSE2101 alone or in combination with pembrolizumab) versus best supportive care in patient with pla… Ended

2024-516096-32-00 Phase II 3 countries Asso De Recherche Cancers Gynecologiques

Showing 1–6 of 6 trials

← All drugs A–Z